^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Brukinsa (zanubrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1902 Broad Superiority of Zanubrutinib (Zanu) Over Bendamustine + Rituximab (BR) Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Phase 3 SEQUOIA Study in Patients With Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) without del(17p)
Published date:
11/02/2023
Excerpt:
Pts with mutations associated with poor prognosis in CLL had significantly better PFS with zanu than with BR (eg, ATM [P=.02], BRAF [P=.01], NOTCH1 [P<.001], SF3B1 [P<.001]; Table)….TN del(17p)-negative pts with CLL/SLL were evenly distributed between zanu and BR arms in SEQUOIA cohort 1 based on the biomarkers analyzed.
Trial ID:
